How One Biotech Venture Is Breaking The Cost Barrier In Manufacturing MAbs For Infectious Diseases
Executive Summary
Biotech official explains how creating partnerships with NGOs, using innovative cell cloning technology and cutting costs is allowing startup to develop new monoclonal antibody treatments for infectious diseases in developing countries, including a new MAb for Ebola.
You may also be interested in...
Program Participants Urge The FDA To Adopt Some Pharmaceutical Quality Metrics And Avoid Others
Site-based metrics praised; lot acceptance rates, invalidated OOS rates discouraged. Agency official admits some proposed metrics were “not the best.”
EU GMP Annex I Is A Top Priority For EMA While Industry Has Lingering Concerns
Questions about contamination control strategy raised as European Medicines Agency makes EU GMP Annex I revision a top priority in its 2021 work plan.
US FDA Mulls Advance Notice On Domestic Surveillance Inspections Post-COVID
Criticized for giving foreign sites advance notice of inspections, agency is considering giving such notice to domestic sites too even after surprise inspections become possible.